Business Wire

The Estée Lauder Companies Announces Retirement of Alexandra Trower, Executive Vice President, Global Communications

12.4.2021 14:00:00 EEST | Business Wire | Press release

Share

Today, The Estée Lauder Companies (NYSE:EL) (ELC) announced that after 13 years with the company, Alexandra (Alex) Trower, Executive Vice President, Global Communications, will retire effective July 1, 2021. The successor to Alex’s role will be announced at a later date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005450/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alex Trower, Executive Vice President, Global Communications, The Estée Lauder Companies, announces retirement. (Photo: Business Wire)

“Alex has been a highly respected thought-leader, collaborative partner, and a trusted senior business advisor,” said Fabrizio Freda, President and CEO, The Estée Lauder Companies. “Leveraging her deep expertise across financial, corporate, consumer and crisis communications, Alex has continuously evolved our strategic communications priorities to drive and support the rapid growth of our business. She built a truly outstanding, global, multi-disciplinary organization and has led her team with wisdom and grace, continuously strengthening the delicate balance of art and science that is ever-present in the world of communications.”

William P. Lauder, Executive Chairman, The Estée Lauder Companies, added: “Against the backdrop of an increasingly complex global landscape, Alex has delivered thoughtful, effective communications to our valued stakeholders, strategically elevating our winning business narrative, rich culture, compelling heritage and distinctive ELC brand equity. She is an outstanding communicator and skilled strategist, and her incredible character, steadfast integrity and deep empathy will be greatly missed across the organization.”

Since joining The Estée Lauder Companies in 2008, Alex has been the architect of ELC’s Global Communications function as it stands today: a highly operationalized, flexible, worldwide and regional structure that prioritizes local relevance, functional expertise and brand-building acumen. Under her leadership, Global Communications has strategically expanded across regions; and through close partnership with regional and affiliate leaders, the department plays a critical role in supporting the company's continued strong regional growth.

Among her many accomplishments, Alex has strategically elevated the company’s reputation worldwide. In 2016, she oversaw the launch of the company’s refreshed Corporate Brand, which represented a transformational change in where, how and why the company engages with its stakeholders. Through this lens, Alex and her team have enabled the organization to communicate boldly, quickly and in more intentional and transparent ways, with an emphasis on strengthening and modernizing the platforms that most resonate with its audiences.

Alex has been a champion of ELC’s efforts across philanthropy, Citizenship and Sustainability, and Inclusion, Diversity and Equity. She serves as a Board member of The Estée Lauder Companies’ Charitable Foundation, is a founding member of the company’s Diversity Council, and served as the first Executive Co-Sponsor of wELCome, the company’s LGBTQA employee resource group.

Mentoring, leading and cultivating talented women is Alex’s passion, which was borne out of her experience as a student at Hollins University, one of the country’s leading women’s universities, where she now serves as the Chair of the Board of Trustees. In 2018, Alex was recognized by New York Women in Communications with a prestigious Matrix Award, presented to her by William P. Lauder in recognition of her exceptional leadership and contributions across the industry. She served as the Co-Chair of the Board of Directors for the International Women’s Media Foundation (IWMF), which supports female journalists worldwide. In 2014, she received the IWMF’s Corporate Leadership Award in recognition of her more than 15 years of service and fundraising.

“I am incredibly proud of all that my team and I have accomplished,” said Alex Trower. “ELC’s Global Communications organization has consistently advanced ahead of the curve, seamlessly partnering with stakeholders across the company and the industry to drive and support the continued success of our business. While the decision to retire is of course bittersweet, I know that the talented Global Communications team is well positioned for its next chapter of growth. On a personal note, it has been an absolute pleasure to serve in this role alongside the Lauder Family and the exceptional ELC executive leadership team.”

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-L
ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Rainey Mancini
(212) 284-3049

Media Relations:
Jill Marvin
(212) 572-4438

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye